• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6 POS filed by Fresh2 Group Limited

    6/24/24 5:20:34 PM ET
    $FRES
    Medical Specialities
    Health Care
    Get the next $FRES alert in real time by email
    F-6 POS 1 e663737_f6pos-fgl.htm

     

    As filed with the Securities and Exchange Commission on June 24, 2024

    Registration No. 333  -  234548

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________________________________  

     

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY 

    AMERICAN DEPOSITARY RECEIPTS

    ________________

     

    FRESH2 GROUP LIMITED  

    (Exact name of issuer of deposited securities as specified in its charter)

    ________________

     

    N/A 

    (Translation of issuer’s name into English)

    ________________

     

    British Virgin Islands 

    (Jurisdiction of incorporation or organization of issuer)

    _____________________________________

     

    CITIBANK, N.A.

    (Exact name of depositary as specified in its charter)

    ________________

     

    388 Greenwich Street 

    New York, New York 10013

    (877) 248 - 4237

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

    ________________

     

    Fresh2 Group Limited

    880 3RD AVE FL 7

    New York, NY 10022

    United States

    (Address, including zip code, and telephone number, including area code, of agent for service)

    _____________________________________

     

    Copies to:

     

    Carter Ledyard & Milburn LLP

    28 Liberty Street, 41st Floor,

    New York, NY 10005

    (212) 238 8844

     

     

    Herman H. Raspé, Esq.

    Patterson Belknap Webb & Tyler LLP

    1133 Avenue of the Americas

    New York, New York 10036

    (212) 336-2301

     

    _____________________________________

     

      It is proposed that this filing become effective under Rule 466: ☐ immediately upon filing.  
        ☐ on (Date) at (Time).

     

    If a separate registration statement has been filed to register the deposited shares, check the following box: ☐

     

    The Registrant hereby amends this Post-Effective Amendment No. 2 to Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Post-Effective Amendment No. 2 to Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Post-Effective Amendment No. 2 to Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

     

    This Post-Effective Amendment No. 2 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

     

      

    ii

     

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

      

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

         
    1. Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
           
    2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
             
    Terms of Deposit:    
      (i) The amount of deposited securities represented by one American Depositary Share (“ADSs”)   Face of Receipt  - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt  - Paragraphs (17) and (18).
             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
             
      (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt  - Paragraph (14);
    Reverse of Receipt - Paragraph (17) and (18).
             
      (v) The sale or exercise of rights  

    Reverse of Receipt – Paragraphs (15) and (17).

             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt - Paragraphs (6);

    Reverse of Receipt - Paragraphs (15), (17) and (19).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
             
      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).
             

       

    I-1

     

     

     

    Item Number and Caption  

    Location in Form of American

    Depositary Receipt (“Receipt”)

    Filed Herewith as Prospectus

             

      (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt – Paragraphs (2), (4), (6), (7), (9), and (10).
             
      (x) Limitation upon the liability of the Depositary  

    Face of Receipt - Paragraph (8);

    Reverse of Receipt - Paragraphs (20) and (21).

             
      (xi) Fees and charges which may be imposed directly  or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
             
    Item 2.  AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

     

     

    Fresh2 Group Limited (the “Company”) is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, is required to file or submit certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

       

    I-2

     

     

     

     

    PROSPECTUS

     

    The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Amendment No. 2 to Deposit Agreement filed as Exhibit (a)(i) to this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 and is incorporated herein by reference.

     

     

    I-3

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)(i) Form of Amendment No. 2 to the Deposit Agreement, by and among the Fresh2 Group Limited (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Filed herewith as Exhibit (a)(i).

     

    (a)(ii) Amendment No. 1 to the Deposit Agreement, dated as of November 4, 2022, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”).___ Filed herewith as Exhibit (a)(ii).

     

    (a)(iii) Deposit Agreement, dated as of February 3, 2020, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”).___ Previously filed as Exhibit (a)(ii) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. no.: 333-234548) with the Commission on October 24, 2022.

     

    (b)(i) Convertible Note Side Letter between the Company and the Depositary, dated as of January 25, 2024. ___Filed herewith as Exhibit (b)(i).

     

    (b)(ii) Warrant Exercise Letter Agreement between the Company and the Depositary, dated as of January 25, 2024. ___Filed herewith as Exhibit (b)(ii).

     

    (b)(iii) Warrant Exercise Letter Agreement between the Company and the Depositary, dated as of January 25, 2024. ___Filed herewith as Exhibit (b)(iii).

     

    (b)(iv) Convertible Note Side Letter between the Company and the Depositary, dated as of September 29, 2023. ___Filed herewith as Exhibit (b)(iv).

     

    (b)(v) Warrant Exercise Letter Agreement between the Company and the Depositary, dated as of May 22, 2023. ___ Filed herewith as Exhibit (b)(v).

     

    (b)(vi) Convertible Debenture Side Letter between the Company and the Depositary, dated as of April 22, 2022. ___ Previously filed as Exhibit (b)(i) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. no.: 333- 234548) with the Commission on October 24, 2022.

      

    II-1

     

     

     

    (b)(vii) Convertible Note Side Letter between the Company and the Depositary, dated as of July 23, 2021. ___ Previously filed as Exhibit (b)(ii) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. no.: 333- 234548) with the Commission on October 24, 2022.

     

    (b)(viii) Convertible Note Side Letter between the Company and the Depositary, dated as of March 16, 2021. ___ Previously filed as Exhibit (b)(iii) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. no.: 333- 234548) with the Commission on October 24, 2022.

     

    (b)(ix) Convertible Note Side Letter between the Company and the Depositary, dated as of August 7, 2020. ___ Previously filed as Exhibit (b)(iv) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. no.: 333- 234548) with the Commission on October 24, 2022.

     

    (b)(x) Custodian Services Agreement for Structural Safekeeping Account between the Company and the Depositary, dated August 7, 2020. ___ Previously filed as Exhibit (b)(v) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. no.: 333- 234548) with the Commission on October 24, 2022.

     

    (c)  Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

     

    (d)  Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ None.

     

    (e)  Certificate under Rule 466. ___ None.

     

    (f)  Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

     

    II-2

     

     

    Item 4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

      

    II-3

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, dated as of February 3, 2020 (the “Deposit Agreement”), by and among Fresh2 Group Limited, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 24th day of June 2024.

      

     

    Legal entity created by the Deposit Agreement, as amended, under which the American Depositary Shares registered thereunder are issued, each American Depositary Share representing the right to receive the specified number of Class A ordinary shares of Fresh2 Group Limited

     

    CITIBANK, N.A., solely in its capacity as Depositary

         
      By:  /s/ Joseph Connor
        Name:  Joseph Connor
        Title:    Attorney-in-Fact

     

    II-4

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Fresh2 Group Limited certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in New York, New York, on June 24, 2024.

       

     

    FRESH2 GROUP LIMITED

         
      By:   /s/ Haohan XU
      Name:  Haohan XU
      Title:    Chief Executive Officer

     

    II-5

     

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Haohan Xu to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 has been signed by the following persons in the following capacities on June 24, 2024.

     

    Signature   Title
         

    /s/ Haohan Xu
     

    Chief Executive Officer and Director

    Name: Haohan Xu    
         

    /s/ Xiaoyu Li
     

    Chief Finance Officer / Chief Accounting Officer and Director

    Name: Xiaoyu Li    
         
    /s/ Honggang Tian   Director
    Name: Honggang Tian    
         

    /s/ Zhigang Zhao
      Director
    Name: Zhigang Zhao    

     

    II-6

     

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT1

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Fresh2 Group Limited has signed this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 in New York on June 24, 2024.

      

    Authorized U.S. Representative:

     

    Fresh2 Group Limited 

     
         
    By:   /s/ Haohan Xu  
     

    Name: Haohan Xu

    Title: Chief Executive Officer

     

     

    II-7

     

     

     

    Index to Exhibits

     

    Exhibit Document

    Sequentially

    Numbered Page

         
    (a)(i) Form of Amendment No. 2 to Deposit Agreement  
         
    (a)(ii) Amendment No. 1 to Deposit Agreement  
         
    (b)(i) Convertible Note Side Letter  
         
    (b)(ii) Warrant Exercise Letter Agreement  
         
    (b)(iii) Warrant Exercise Letter Agreement  
         
    (b)(iv) Convertible Note Side Letter  
         
    (b)(v) Warrant Exercise Letter Agreement  
         

     

    Get the next $FRES alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresh2 Group Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing

    New York, NY, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or the "Company"), a  B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on October 16, 2024, it received a Staff Determination Letter from the Nasdaq Stock Market LLC ("Nasdaq")  indicating that the Company did not comply with Nasdaq's filing requirements as set forth in Listing Rule 5250(c)(1). The letter is a result of the Company's failure to file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, and June 30, 2024, within the required deadlines. Nasdaq had previously granted

    10/17/24 4:05:00 PM ET
    $FRES
    Medical Specialities
    Health Care

    Fresh2 Group Ltd. Announces Receipt of an Additional Delinquency Compliance Alert Notice from Nasdaq

    New York, NY, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or the "Company"), a  B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on August 19 , 2024, it received an additional delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising they have not received the Company's Form 10-Q for the period ended June 30, 2024, it does not comply with the Listing Rules 5250(c)(1) (the "Rules"), which requires the timely filing of all required periodic reports with the SEC. Previously, Nasdaq Staff had granted the Company an exception

    8/22/24 4:05:00 PM ET
    $FRES
    Medical Specialities
    Health Care

    Fresh2 Announces Collaboration with Over 50 Influencers in Video E-commerce

    New York, NY, July 16, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or "the Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that its video e-commerce business has partnered with over 50 influencers, resulting in continued rapid sales growth. By leveraging these key partnerships, Fresh2's video e-commerce business is rapidly expanding its market presence in the e-commerce sector. (Screenshot of some Company's venues at tiktok) The Power of Video E-commerce Unlike traditional e-commerce, video e-commerce uses multimedia formats, which offer stronger visual appeal and can hi

    7/16/24 9:15:00 AM ET
    $FRES
    Medical Specialities
    Health Care

    $FRES
    SEC Filings

    View All

    SEC Form 6-K filed by Fresh2 Group Limited

    6-K - Fresh2 Group Ltd (0001786511) (Filer)

    12/23/24 4:02:53 PM ET
    $FRES
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Fresh2 Group Limited

    6-K - Fresh2 Group Ltd (0001786511) (Filer)

    11/14/24 4:15:32 PM ET
    $FRES
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Fresh2 Group Limited

    6-K - Fresh2 Group Ltd (0001786511) (Filer)

    7/24/24 4:01:19 PM ET
    $FRES
    Medical Specialities
    Health Care

    $FRES
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of New Independent Director

    NEW YORK, Dec. 15, 2023 /PRNewswire/ -- Fresh2 Group Ltd. (NASDAQ:FRES) ("Fresh2" or "the Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced the appointment of Zhijun (Michael) Liang, as an independent director of the Company, effective January 1, 2024. Zhijun (Michael) Liang, has spent more than two decades providing management consulting and investment management services, primarily to start-ups and growth businesses, enabling them to address expansion needs and financial challenges. He co-founded Beijing Yuantong Funds Management Co., Ltd., and has led its risk and investment management since 2018. Concurrently, as the

    12/15/23 4:01:00 PM ET
    $FRES
    Medical Specialities
    Health Care

    Fresh2 Group Ltd. Appoints New Chief Strategy Officer to Drive Advancement and Execution of Long-Term Growth Strategy

    NEW YORK, July 26, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ:FRES) ("Fresh2," the "Company" or "we"), a company with operations in the United States and China focused on the business-to-business e-commerce and supply chain sectors for the restaurant supply and food industry and on early cancer screening and detection,  today announced the appointment of Mr. Yidong Hu as its Chief Strategy Officer (CSO) effective on July 21, 2023. Mr. Hu was appointed to drive the advancement and execution of the Company's long-term strategy. Mr. Hu is a seasoned executive with over a decade of experience in the media and finance sectors. Mr.Hu has served as

    7/26/23 9:00:00 AM ET
    $FRES
    Medical Specialities
    Health Care